Spravato and Insurance in California: What Coverage Actually Requires

Most commercial insurance plans, Medicare, and CalOptima/Medi-Cal cover Spravato in California when a patient meets the clinical criteria for treatment-resistant depression and the treatment is administered at a REMS-certified clinic. Coverage is never automatic. It depends on documented prior antidepressant trials, a confirmed diagnosis, and prior authorization from the specific plan. For eligible commercially insured patients, a manufacturer savings program can bring the per-session cost down to as little as $10.

Here is what that actually requires, plan by plan, for patients in Orange County.

Is Spravato Covered by Insurance in California?

Spravato is FDA-approved, which is what gives it an insurance pathway that off-label treatments do not have. Most commercial plans, Medicare, and CalOptima/Medi-Cal cover it in California when a patient’s history meets the plan’s criteria and the medication is administered at a certified clinic.

Finding out that Spravato is covered tends to change the tone of a first conversation. As Dr. Stefani LaFrenierre, Resiliency’s founding psychiatrist, puts it:

“Once we explain the Spravato copay assistance program, you can hear the relief. Patients realize their costs will be minimal, and they feel even further supported in their treatment journey here at Resiliency.”

Coverage is plan-specific, not universal. Two patients with the same diagnosis can see different outcomes depending on their insurer’s documentation requirements, their plan’s prior authorization process, and whether they’re on a commercial plan, Medicare, or Medi-Cal. That’s part of why Resiliency verifies benefits directly with each patient’s plan rather than quoting a single answer for everyone who calls.

For eligible patients with commercial insurance, Spravato’s manufacturer savings program, Spravato withMe (independent of Resiliency), can bring the cost down to as little as $10 per session, subject to program terms. Medicare and CalOptima/Medi-Cal patients are not eligible for that program, but for CalOptima/Medi-Cal members who meet the clinical criteria, the plan itself covers treatment in full.

What stays consistent across every plan type is the clinical bar: insurers are covering Spravato for a specific condition, treatment-resistant depression, not for depression broadly. That distinction is what the next section covers.

What Do Insurers Look for Before Approving Spravato?

Insurers use a specific, published definition of treatment-resistant depression (TRD) to decide who qualifies. The FDA and the European Medicines Agency define TRD as an inadequate response to at least two different antidepressants, each taken at an adequate dose for an adequate length of time. Researchers estimate at least 30% of people with depression meet that definition, which is also roughly the population insurers are willing to approve Spravato for.

In practice, that means a plan typically wants documentation of which antidepressants a patient already tried, how long they tried them, and why each one didn’t work (no response, partial response, or side effects severe enough to stop). A current diagnosis of major depressive disorder is part of that picture too.

Insurers scrutinize this closely for a reason. Research on treatment-resistant depression notes that a meaningful share of patients who appear treatment-resistant are actually what researchers call pseudo-resistant, meaning the prior antidepressant trials were inadequate in dose, duration, or adherence rather than genuinely ineffective. That’s part of why a plan wants specifics, not just a list of medication names, before approving Spravato.

Many plans also want that documentation anchored to a standardized symptom-rating tool, not just a provider’s narrative notes. Scales like the Hamilton Depression Rating Scale, the Quick Inventory of Depressive Symptomatology, or the Montgomery-Asberg Depression Rating Scale give a reviewer an objective baseline to compare against follow-up scores, which is part of why Resiliency documents symptom severity using validated instruments rather than narrative description alone.

This is a clinical determination, made by a provider during an evaluation, not a box a patient checks on an intake form. Resiliency’s evaluation process exists specifically to build that documentation accurately the first time, since an incomplete record is one of the most common reasons a prior authorization request stalls.

None of this is unique to Resiliency. It’s the same bar every Spravato-prescribing practice and every covering insurer in California works from, which is also why a thorough evaluation matters regardless of which plan a patient carries.

Does CalOptima or Medi-Cal Cover Spravato in Orange County?

Yes, through Resiliency, and this is a real gap in the local market. Resiliency is in-network with CalOptima Health, Orange County’s public health insurance plan, for both Deep TMS and Spravato with prior authorization. Many Orange County psychiatric practices don’t accept CalOptima at all for interventional treatment, which leaves Medi-Cal members with far fewer local options for Spravato than commercially insured patients have.

CalOptima coverage follows the same clinical logic as commercial plans: a confirmed TRD diagnosis, documented prior antidepressant trials, and administration at a REMS-certified clinic. The practical difference is access. Roughly a third of California’s population is covered by Medi-Cal, and a meaningful share of people who could benefit from Spravato simply don’t have a nearby in-network provider.

Resiliency’s team handles CalOptima prior authorization directly with the plan, the same way it does for commercial insurance, so a Medi-Cal member isn’t navigating that process alone or assuming coverage doesn’t exist because it’s harder to find information about.

For a Medi-Cal member who meets criteria, coverage can extend past the treatment itself to transportation to and from appointments. That matters more for Spravato than for most treatments, since patients can’t drive themselves home after a session.

This gap isn’t unique to Spravato. Orange County has relatively few psychiatric practices that accept Medi-Cal for any interventional treatment, Deep TMS included, which is part of why a local, in-network option matters more here than the simple fact of CalOptima covering the treatment on paper.

Medicare and Medicare Advantage plans typically cover Spravato on similar clinical terms, with their own prior authorization and documentation requirements specific to each plan.

How Does Coverage Differ Between Commercial Insurance, Medicare, and Medi-Cal?

Insurance coverage for Spravato follows the same clinical bar across every type of plan: a confirmed treatment-resistant depression diagnosis, documented prior antidepressant trials, and administration at a REMS-certified clinic. What differs is the paperwork, the authorization timeline, and who qualifies for additional cost assistance.

Commercial plans vary the most from payer to payer. A prior authorization request that satisfies one insurer may need more detail for another, and commercial patients are the only group eligible for Spravato’s manufacturer savings program, which can reduce the per-session cost substantially for those who qualify.

Medicare and Medicare Advantage plans cover Spravato on similar clinical terms, but authorization runs through Medicare’s own review process rather than a commercial payer’s. A Medicare Advantage plan’s specific prior authorization rules can differ from traditional Medicare, so Resiliency verifies which type of Medicare coverage a patient has before submitting anything.

CalOptima and other Medi-Cal managed care plans add a layer most patients don’t expect: provider network limitations. Even when Medi-Cal covers Spravato in principle, a patient still needs an in-network, REMS-certified provider willing to take Medi-Cal for interventional psychiatry, a shorter list than commercial insurance offers in Orange County. Resiliency’s CalOptima network status is what closes that gap for local Medi-Cal members.

None of this changes the underlying clinical question an insurer is answering: documented trial and failure of prior antidepressants, confirmed treatment-resistant depression. It only changes how that documentation gets submitted, how long the response takes, and what a patient pays once approved.

Patients who are dual-eligible for Medicare and Medi-Cal go through a coordination process between the two programs, with Medicare typically acting as the primary payer and Medi-Cal covering what Medicare doesn’t. Resiliency’s team navigates that coordination the same way it handles single-payer authorization, rather than leaving a dual-eligible patient to figure out which program to contact first.

What Does Spravato Cost Without Insurance?

Self-pay cost for Spravato varies by dose, session frequency, and whether in-office monitoring is billed separately, so a single national number rarely reflects what a specific patient would actually pay. Patients weighing the self-pay route are better served by a direct cost estimate from the clinic administering treatment than by a generic online figure.

For patients who do have insurance but face a high deductible or a denial, the Spravato manufacturer offers its own savings program, separate from any insurance plan, that can reduce the per-session cost for commercially insured patients who qualify. Medicare and Medi-Cal patients typically aren’t eligible for that specific program, since it’s designed around commercial plan structures, but their own plan’s cost-sharing rules still apply.

Cost is rarely the full picture on its own. A patient paying cash for Spravato is also committing to a REMS-certified in-office visit with a required two-hour monitoring period, multiple times a week during induction, which is a real time cost on top of the dollar figure.

Patients who do end up paying out of pocket, whether by choice or because a plan denies coverage, go through the same REMS-certified clinic process as insured patients. Resiliency works out a payment arrangement before scheduling a self-pay patient’s first dose, the same sequencing used for patients waiting on insurance authorization, so nobody shows up for a session that hasn’t been confirmed as paid for.

Patients who want an actual number for their situation, not a national estimate, can call (949) 996-5355 or reach out through Resiliency’s contact page for a cost breakdown based on their specific coverage.

How Long Does Spravato Insurance Authorization Take, and What If It’s Denied?

Timelines vary by plan and by how complete the initial documentation is. Some insurers respond to a prior authorization request within days. Others take longer, and a plan can request additional records before making a decision, which restarts part of the clock.

A thorough evaluation is what keeps that timeline as short as it can be. When the initial submission already documents prior antidepressant trials, symptom severity, and a clear TRD diagnosis, there’s nothing left for a reviewer to request before approving.

A denial isn’t necessarily final. The most common next step is an appeal built around the same documentation: what was tried, for how long, and why it didn’t work, often with additional detail a reviewer specifically asked about. Resiliency’s team manages that appeal process directly with the payer rather than leaving a patient to resubmit paperwork on their own.

Many appeals also include the option for a peer-to-peer review: a direct conversation between the prescribing provider and the plan’s own medical reviewer, rather than relying on paperwork alone. That conversation can resolve a denial faster than a written appeal on its own, since it lets a provider answer a reviewer’s specific question about the case in real time instead of guessing what additional documentation might satisfy it.

If an appeal is also denied, patients generally have the right to request an independent external review, a process required under California and federal insurance law where a reviewer outside the insurance company evaluates the denial. Resiliency can provide the clinical documentation needed for that request, though the review itself is handled through the patient’s plan and state regulators rather than the practice.

Patients with CalOptima, Medicare, or commercial insurance all go through a version of this same process. The specific forms and timelines differ by plan, but the underlying question every insurer is answering is the same one covered above: does this patient’s documented history meet the clinical bar for treatment-resistant depression.

Frequently Asked Questions

Patients with questions about their own coverage can call (949) 996-5355 or reach out through Resiliency’s contact page. Benefits verification starts there.